DE69120303T2 - Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus - Google Patents

Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus

Info

Publication number
DE69120303T2
DE69120303T2 DE69120303T DE69120303T DE69120303T2 DE 69120303 T2 DE69120303 T2 DE 69120303T2 DE 69120303 T DE69120303 T DE 69120303T DE 69120303 T DE69120303 T DE 69120303T DE 69120303 T2 DE69120303 T2 DE 69120303T2
Authority
DE
Germany
Prior art keywords
conjugates
biologically stable
stable polymers
polynucleotides
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69120303T
Other languages
English (en)
Other versions
DE69120303D1 (de
Inventor
Michael J Conrad
Stephen Coutts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Application granted granted Critical
Publication of DE69120303D1 publication Critical patent/DE69120303D1/de
Publication of DE69120303T2 publication Critical patent/DE69120303T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
DE69120303T 1990-01-16 1991-01-15 Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus Expired - Fee Related DE69120303T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46613890A 1990-01-16 1990-01-16
US07/494,118 US5162515A (en) 1990-01-16 1990-03-13 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
DE69120303D1 DE69120303D1 (de) 1996-07-25
DE69120303T2 true DE69120303T2 (de) 1996-11-28

Family

ID=27041547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69120303T Expired - Fee Related DE69120303T2 (de) 1990-01-16 1991-01-15 Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus

Country Status (15)

Country Link
US (2) US5162515A (de)
EP (1) EP0438259B1 (de)
JP (2) JPH05505520A (de)
AT (1) ATE139448T1 (de)
AU (1) AU640730B2 (de)
CA (2) CA2173878C (de)
DE (1) DE69120303T2 (de)
DK (1) DK0438259T3 (de)
ES (1) ES2090233T3 (de)
FI (1) FI107514B (de)
GR (1) GR3021113T3 (de)
IE (1) IE910131A1 (de)
NO (1) NO303940B1 (de)
PT (1) PT96503B (de)
WO (1) WO1991010426A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447722A (en) * 1983-12-12 1995-09-05 University Of Manitoba Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
US5391785A (en) * 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
DK0642798T3 (da) * 1993-09-08 2007-09-10 Jolla Pharma Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5599912A (en) * 1993-09-10 1997-02-04 Coretech, Inc. Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5681700A (en) * 1994-05-25 1997-10-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
US6280944B1 (en) 1994-05-25 2001-08-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
EP0824541B1 (de) * 1995-05-04 2009-12-16 Gilead Sciences, Inc. Nukleinsäureligand-komplexe
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6410775B1 (en) 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1999055363A1 (en) 1998-04-27 1999-11-04 Biocrystal Ltd. Compositions and methods for tolerization in immune complex-mediated disease progression
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
MXPA02005236A (es) * 1999-11-28 2004-03-19 Jolla Pharma Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
US6911535B2 (en) * 2000-03-22 2005-06-28 Solvlink Biosciences Biomolecule/polymer conjugates
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
EP1387697A4 (de) * 2001-05-17 2005-04-20 Jolla Pharma Verfahren zur behandlung von antikörper-vermittelten erkrankungen unter verwendung von mitteln zur hemmung von cd21
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
US20050266427A1 (en) * 2002-01-15 2005-12-01 Schwartz David A Biomolecule/polymer conjugates
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
NZ542687A (en) * 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
WO2012138694A2 (en) * 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
CN113150064B (zh) * 2021-04-14 2023-04-11 中山大学 一种抗菌抗虫肽的人工合成方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1989009628A1 (en) * 1988-04-04 1989-10-19 Potempa Lawrence A Binding of immune complexes by modified forms of c-reactive protein
EP0572443A1 (de) * 1990-12-17 1993-12-08 The Johns Hopkins University Unterdrückung von immunantworten durch oligomere formen von antigenen mit kontrollierter chemie

Also Published As

Publication number Publication date
ES2090233T3 (es) 1996-10-16
NO303940B1 (no) 1998-09-28
FI107514B (fi) 2001-08-31
EP0438259B1 (de) 1996-06-19
CA2034197A1 (en) 1991-07-17
IE910131A1 (en) 1991-07-17
CA2173878A1 (en) 1991-07-17
NO922781D0 (no) 1992-07-14
EP0438259A1 (de) 1991-07-24
JP2001354569A (ja) 2001-12-25
AU6941891A (en) 1991-07-18
FI923241A0 (fi) 1992-07-15
DK0438259T3 (da) 1996-07-15
NO922781L (no) 1992-07-14
AU640730B2 (en) 1993-09-02
ATE139448T1 (de) 1996-07-15
FI923241A (fi) 1992-07-15
US5162515A (en) 1992-11-10
CA2034197C (en) 2001-07-17
WO1991010426A1 (en) 1991-07-25
CA2173878C (en) 2000-04-04
PT96503A (pt) 1991-10-31
US5276013A (en) 1994-01-04
JPH05505520A (ja) 1993-08-19
DE69120303D1 (de) 1996-07-25
GR3021113T3 (en) 1996-12-31
PT96503B (pt) 1998-07-31

Similar Documents

Publication Publication Date Title
ATE139448T1 (de) Konjugate aus biologisch stabilen polymeren und polynukleotiden zur behandlung von systematischem lupus erythematosus
CA2171434A1 (en) Chemically-defined non-polymeric valency platform molecules and conjugates thereof
BR9509730A (pt) Compostos polinucleotidíeos
DE3852982D1 (de) Funktionelle leitungsfähige Polymere und ihre Verwendung in Diagnosegeräten.
DE59008217D1 (de) Hydrophile quellfähige Pfropfpolymerisate, deren Herstellung und Verwendung.
FR2614026B1 (fr) Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
DE3887280D1 (de) Hydrophile quellbare Pfropfpolymerisate, deren Herstellung und Verwendung.
DE3850544T2 (de) Mikrosonde, deren Herstellung und elektronisches Gerät, das diese Mikrosonde gebraucht.
ATE151076T1 (de) Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-internucleotidverknüpfungen
DE69004933T2 (de) Vernetzter fester Polymerelektrolyt.
DE3587486T2 (de) Imidazolinone enthaltende Polymere und Copolymere.
DE68916357D1 (de) Kern-Schale-Polymer, Zusammensetzung und Formteile davon.
EP1808183A3 (de) Chemisch definierte nichtpolymere Valenzplattformmoleküle und Konjugate davon
JPS6465135A (en) Crosslinked organosiloxane polymer
DE69229075T2 (de) Partikelförmiges isocyanuratringhaltiges vernetztes Polyurethan-Polyharnstoffpolymer und Verfahren zu seiner Herstellung
DE69706989T2 (de) Konjugate aus einem oligonukleotid und einem elektronisch leitfähigem polymer mit einem molekül von interesse und deren verwendung
DE69014655T2 (de) Schlagfeste Polymermischungen aus Polyamiden, Anhydridcopolymeren und funktionalisierten Elastomeren.
DE3785482D1 (de) Hochfestigkeit und hochbiegsamkeit erzeugende polymerzusammensetzung.
DE68914052T2 (de) Poly(arylenthioäther)copolymere und Verfahren zu ihrer Herstellung.
JPS6448819A (en) Non-meltable polymer, manufacture and use as electroconductive polymer
ATE23352T1 (de) Stabilisatoren fuer halogenhaltige polymere, diese enthaltende polymerzusammensetzungen und daraus hergestellte geformte gegenstaende.
ATE49319T1 (de) Elektrisch leitfaehiges kunststoffmaterial und verfahren zu seiner herstellung.
RU97106026A (ru) Суппозитории вагинальные для лечения трихомонадного и неспецифичного кольпитов

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee